Three Sessions and a Shrug

A client finishes a psilocybin session at an Oregon service center and asks a reasonable question: what integration support should I get? The marketplace has answers. A free journaling PDF. A $50 integration circle. A coach at $150 a month. A therapist at $200 an hour. A $3,000 retreat package. Every offer is presented with identical confidence, and not one of them can point to a study showing that its version of integration produces better outcomes than any other, or than none.

That's not a gap in the marketing. It's a gap in the science, and it sits under the single most repeated claim in this field, one I've made myself, in print, more than once: integration is where the lasting change happens. I believe that claim. I also went looking for the psychedelic integration research that would let me defend it to a skeptical colleague, and I want to show you what's actually there.

Integration isn't a fringe add-on in research protocols; it's universal. Across the current trial landscape, the standard architecture is remarkably consistent: typically two preparation sessions, a dosing session, and three integration sessions afterward. The Sheppard Pratt suicidal-ideation trial used three. Compass's Phase 3 program builds them in. The protocol structure repeats across registered studies in PTSD, anorexia, substance use disorders, and end-of-life distress.

Here's what should bother you: that number, three, is a convention, not a finding. No dose-finding work sits behind it. A 2021 systematized review in the American Journal of Psychotherapy examined the psychotherapeutic components across 25 years of psilocybin trials and found broad commonality in the three-stage structure, real inconsistency in what the therapy actually was, and concluded that "additional research is needed to identify the unique effect of psychotherapy" in these treatments. The sessions are everywhere. The evidence for them is nowhere in particular.

Before writing this post I ran a PubMed sweep, and I'll disclose the headline result: a title search for "psychedelic integration" returns six articles. Total. Here's the inventory of what exists, because it's genuinely useful work and worth knowing:

• A definition. Bathje and colleagues (2022) published the first full concept analysis, synthesizing the many competing definitions and practices into a coherent model, and documenting along the way just how much confusion the term contains.
• Guidelines. An international working group produced practice guidelines for mental health professionals (2023), built from literature review and roundtable consensus, because graduate training prepares almost nobody for this work.
• Measurement tools. The Psychedelic Integration Scales (2022) give researchers validated instruments for measuring integration engagement and experience. Instruments built, outcomes not yet measured with them at scale.
• A call for evidence. Most telling: a 2023 paper in Experimental and Clinical Psychopharmacology titled, in effect, please study this, which states plainly that the existing integration models, theory-driven and clinically seasoned as some are, "each lack any empirical support and thus cannot be described as evidence based".

Definitions, guidelines, scales, and a call for research. What's missing from that list is the thing itself: an outcome study.

Let me state the gap precisely, because absence-of-evidence claims deserve precision. Trials include integration sessions, and the treatments work in those trials, so integration is part of an effective package. But no published trial has isolated integration as a variable: dosing with three integration sessions versus none, three versus six, this model versus that one, therapist-delivered versus peer-delivered. The trials that exist, including well-designed RCTs, embed preparation and integration as a fixed package wrapped around the drug. We know the package can work. We don't know what the integration component contributes, how much of it is needed, or what should happen inside it.

So the field's central claim, mine included, currently rests on clinical consensus, theoretical coherence, and the accumulated judgment of practitioners. That's not nothing; most of psychotherapy's history ran on exactly that before trials caught up, and the conceptual work above is how a field gets ready to do better science. But consensus is what we have, and we should say so.

Partly, integration is genuinely hard to operationalize. It spans journaling, therapy, community, meaning-making, and behavior change, on no fixed timeline, with no agreed endpoint; the concept-analysis literature exists precisely because nobody could agree on what the construct was.

And partly, follow the funding. Drug trials answer drug questions, because approval, patents, and revenue attach to the molecule. Nobody owns integration. A pharmaceutical company has no financial reason to fund a dismantling study that might show its product needs six expensive therapy sessions to deliver durable outcomes, and every reason not to fund one that might show the cheaper arm does fine. Meanwhile the same question haunts ketamine, where a real-world study found no added benefit from psychotherapy and a randomized trial is only now underway. The least studied component of psychedelic treatment is the one with no patent on it. That's not a conspiracy. It's the ordinary physics of what gets funded, and it's why public money, like NIDA's new Oregon study, matters disproportionately here.

I sell integration training, including a free guide, so read this section knowing my stake. Here's what I think honest practice looks like while the evidence catches up:

1. Tell clients the truth about the evidence status. "Integration support is standard in every trial, and we don't yet have research isolating how much it adds" is an honest sentence that almost nobody in the marketplace says out loud. Say it.
2. Anchor to what is evidence-based. The skills inside good integration work, therapeutic alliance, behavioral activation, meaning-focused work, trauma-informed care, carry their own evidence bases from general psychotherapy research. Lean on those, not on integration mystique.
3. Measure something. The Psychedelic Integration Scales exist. A practice that tracks even simple outcomes is contributing more to this question than one that doesn't.
4. Watch for the research when it lands. The conceptual groundwork (definition, guidelines, instruments) is recent and deliberate; outcome studies are the obvious next step, and the first dismantling trial will be field-defining news.

The gap will close. When it does, some of what we all believe about integration will be confirmed, and some of it won't survive contact with the data, and clinicians who built their practice on honest foundations will have nothing to walk back.

Not yet, in the strict sense. A title search for "psychedelic integration" returns only a handful of articles: a concept analysis, practice guidelines, validated scales, and a call for research. No outcome study has tested whether integration improves results. Its skills, like alliance and meaning-focused work, draw on general psychotherapy evidence, but integration itself lacks direct empirical support.

Nobody knows. Trials standardize around three integration sessions, but that number is a convention with no dose-finding work behind it. No study has compared three sessions versus none, or three versus six. The honest answer is that the optimal number, format, and content of integration have not been established by research.

Two reasons. Integration is genuinely hard to operationalize, spanning journaling, therapy, community, and behavior change with no agreed endpoint. And funding follows the molecule: drug trials answer drug questions, and nobody owns or patents integration, so there is little commercial incentive to study it. Public funding, like NIDA's Oregon study, matters disproportionately here.

Tell clients the truth about the evidence status, and anchor to skills that are evidence-based: alliance, behavioral activation, meaning-focused and trauma-informed work. Scale fees to the uncertainty rather than charging premium rates for an unvalidated component, and measure outcomes where you can, using tools like the Psychedelic Integration Scales.

If your clients are coming to you after psychedelic experiences and you want a structured, no-cost starting point for the work in the meantime: